Craig P. Ramirez, Ph.D.
Co-Founder & Chief Executive Officer
Dr. Ramirez is a cancer cell biologist by training. He was previously a post-doctoral researcher in the Developmental Therapeutics Lab at UT Austin Dell Medical School. Dr. Ramirez obtained his doctorate in cancer cell biology at NYU School of Medicine under the leadership of Dr. Dafna Bar-Sagi, a world-renowned expert in pancreatic and Ras-driven cancers. During his time in the lab, Dr. Ramirez uncovered novel therapeutic targets and MOAs, several of which represent the backbone of Tezcat's technology platform. In addition to research, Dr. Ramirez has been engaged in various entrepreneurship and executive programs, including Entrepreneurship Lab (Bio and Health Tech NYC) and the Texas Medical Center Accelerator for Cancer Therapeutics, to further develop the core skill sets and relationships for successful biotech ventures.
Andrew D. Hauser, Ph.D.
Co-Founder & Chief Operating Officer
Dr. Hauser is a trained molecular biologist with more than 10 years of experience in cancer research. He obtained his Ph.D. in the lab of Dr. Carol Williams at the Medical College of Wisconsin followed by a post-doc in the lab of Dr. Dafna Bar-Sagi at NYU. In addition to his scientific expertise, he obtained broad experience in project and team management. He previously acted as the Research Integrity & Compliance Senior Specialist at NYU where he ensured that biomedical research is conducted in accordance with applicable legal, regulatory and contractual obligations. This included grant administration, sponsored program management, clinical trials, FDA rules and regulations, intellectual property, data management, acquisition and sharing, and data privacy/security.
Alex M. Efron, M.B.A.
Alex brings over a decade of healthcare industry experience to his advisory role at Tezcat. Prior to co-founding Tezcat, Alex was a management consultant, directing strategy, data analytics, regulatory compliance, and profit improvement initiatives for pharmaceutical and biotechnology companies, managed care organizations, and health systems. In addition to consulting, Alex has held investing and finance roles at Goldman Sachs, Spring Mountain Capital, and Windham Venture Partners, and he supported business development and clinical operations at IRX Therapeutics, a clinical-stage immuno-oncology company. Alex holds a B.A. in Neuroscience from Pomona College and an M.B.A. from Columbia Business School, where he led the Healthcare Industry Association.